Discover Chronic Intractable Diarrhea: 5 Key Findings About Mastocytic Enterocolitis

Estimated Read Time: Approximately 5-7 minutes

Keywords: Chronic intractable diarrhea, Mast cells, Mastocytic enterocolitis, Immunohistochemical analysis, Mast cell tryptase, Chronic diarrhea, Inflammatory bowel disease, Celiac disease, Histamine receptor antagonists, Mast cell mediator release

Study Authors: Shriram Jakate, MD, FRCPath; Mark Demeo, MD; Rohan John, MD; Mary Tobin, MD; Ali Keshavarzian, MD

This article is a summary and written based on the study in the following link.  

A person in the bathroom clutching their lower back, clearly in discomfort, suffering from chronic intractable diarrhea, a condition associated with increased mucosal mast cells and known as mastocytic enterocolitis. The image reflects the struggle and pain of living with this persistent digestive issue.

Introduction

Chronic intractable diarrhea remains a diagnostic challenge for many patients despite detailed evaluations. Traditional biopsies often appear unremarkable, yet a closer examination of mucosal mast cells reveals significant insights.

Mast Cell Concentration in Chronic Diarrhea

In this study, we examined the concentration of mast cells in colonic or duodenal biopsy specimens from 47 patients with chronic intractable diarrhea. Immunohistochemical analysis for mast cell tryptase was used, comparing results to those from 50 control subjects and 63 patients with other chronic diarrhea diseases, such as inflammatory bowel disease and celiac disease.

Findings

The control group showed an average of 13.3 mast cells per high-power field. In contrast, 33 out of 47 patients with chronic intractable diarrhea had more than 20 mast cells per high-power field. Notably, 67% of these patients experienced symptom relief through drugs affecting mast cell function, such as H1 and H2 receptor antagonists and mast cell mediator release inhibitors.

Mastocytic Enterocolitis: A Novel Diagnosis

The term “mastocytic enterocolitis” has been coined to describe this condition, characterized by increased mucosal mast cells demonstrated through immunohistochemistry. This is distinct from systemic or cutaneous mastocytosis and is not evident in other chronic diarrhea diseases. The increased mast cells are reactive and specific to the gut mucosa, suggesting a gut-specific phenomenon driven by unknown stimuli.

Clinical Implications

Mast cells play a crucial role in regulating intestinal sensory and motor functions, potentially causing diarrhea and abdominal pain through their mediator release. This study emphasizes the importance of considering mast cell function in chronic intractable diarrhea cases, as traditional evaluations might miss this significant factor.

Conclusion

Mastocytic enterocolitis should be considered in patients with chronic intractable diarrhea when routine biopsies appear normal. Immunohistochemical staining for mast cell tryptase can reveal increased mast cells, guiding effective treatment options. Further research is essential to understand the triggers and mechanisms behind this condition.

Visit our resources for more articles.

References

  • Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1464โ€“1486.
  • American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 1999;116:1461โ€“1463.
  • Schiller LR. Chronic diarrhea. Gastroenterology. 2004;127:287โ€“293.
  • Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology. 2002; 122:1701โ€“1714.
  • Stevens RL, Austen KF. Recent advances in the cellular and molecular biology of mast cells. Immunol Today. 1989;10:381โ€“386.
  • Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34โ€€, c-kitโ€€, and expresses aminopeptidase N (CD13). Blood. 1999;94:2333โ€“2342.
  • Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A. 1986;83:4464โ€“4468.
  • Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J Cell Biol. 1996;135:279โ€“290.
  • Marshall JS, Jawdat DM. Mast cells in innate immunity. J Allergy Clin Immunol. 2004;114:21โ€“27.
  • Santos J, Saperas E, Nogueiras C, et al. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998;114:640โ€“648.
  • Wood JD. Enteric neuroimmunophysiology and pathophysiology. Gastroenterology. 2004;127:635โ€“657.
  • Castells MC. Mastocytosis: classification, diagnosis, and clinical presentation. Allergy Asthma Proc. 2004;25:33โ€“36.
  • Miner PB Jr. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol. 1991;96:40Sโ€“44S.
  • Cherner JA, Jensen RT, Dubois A, Oโ€™Dorisio TM, Gardner JD, Metcalfe DD. Gastrointestinal dysfunction in systemic mastocytosis. Gastroenterology. 1988;95: 657โ€“667.
  • Libel R, Biddle WL, Miner PB Jr. Evaluation of anorectal physiology in patients with increased mast cells. Dig Dis Sci. 1993;38:877โ€“881.
  • de Jonge WJ, The FO, van der Coelen D, et al. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology. 2004;127:535โ€“545.

See original study for ALL references

GetReliefRX is a compounding pharmacy dedicated to providing compounded medication covering a range if symptoms.